Business Context and Reporting Period
Aclarion, Inc. (ACON), an emerging growth company incorporated in Delaware, filed this Form 8-K on January 6, 2025, reporting events occurring on January 3, 2025. The company is headquartered in Broomfield, Colorado, and its common stock and warrants trade on the Nasdaq Stock Market.
Key Financial Metrics and Transaction Details
This filing details a registered direct offering rather than periodic financial performance results. Key transaction metrics include:
- Shares Issued: 3,380,276 shares of common stock.
- Price Per Share: $0.142.
- Gross Proceeds: Approximately $0.5 million.
- Placement Agent Fee: 7% of aggregate gross proceeds paid to Dawson James Securities, Inc.
- Use of Proceeds: Market development, clinical evidence, product development, quality assurance, general and administrative support, and other corporate purposes.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and a Placement Agency Agreement on January 3, 2025. This transaction increases the company's share count and capital base. The offering is expected to close on or about January 6, 2025, subject to customary closing conditions.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance clinical evidence and product development. The offering was conducted pursuant to an effective Form S-3 registration statement filed in September 2024. The filing includes a press release furnished under Regulation FD but notes that this information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Confirm the updated share count and potential dilution impact on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions.
- Monitor subsequent filings for updates on the deployment of funds toward clinical evidence and product development.